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Abstract:  
BACKGROUND: Over half of all Americans take prescription medications regularly, and 
commentators have noted that modern society has become overly reliant on “pill-taking.”   
OBJECTIVES: The primary objective of this study was to better understand how healthy 
individuals’ perceive the identity of a “pill-taker,” using Phase I trial participants as a proxy for 
healthy individuals. 
METHODS: This was a mixed methods study that utilized qualitative and quantitative analysis. 
The data source was semi-structured interview transcripts and demographic data (n = 131) from 
the HealthyVOICES project, a 5-year study in the UNC Department of Social Medicine and 
Center for Bioethics. Two sets of interviews were investigated for each participant (n = 261), and 
participants were evaluated as “pill-takers,” “not-pill-takers,” or “ambivalent” based on their 
responses to questions about medications. Secondary coding was conducted on interview 
transcripts to reveal broader themes. Chi-square analyses were conducted to test the relationships 
between sociodemographic factors (age, race, socioeconomic status, and gender) and “pill-
taking” status.  
RESULTS: Chi-square analysis revealed no statistically significant relationship between 
sociodemographic factors and “pill-taking” status. Qualitative analysis revealed four broad 
themes, particularly for not pill-takers and those who were ambivalent: (1) natural/herbal 
remedies are preferable alternatives to pill-taking; (2) pills are dangerous chemicals and harmful 
to the body; (3) healthy individuals can be ambivalent about medications; and (4) pill-taking is 
related to the flawed medication culture in the U.S.  
CONCLUSION: It is possible that pill-taking culture affects demographic groups equally, and 
that there are no significant relationships between sociodemographic characteristics and pill-
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taking status. The qualitative findings indicate that there are strong negative views of pill-taking 
among some healthy volunteers, which could have important implications for adherence to 
medication regimens. When studying healthy individuals in the future, it will be important to 
consider that these individuals may not have fully formed opinions on medications because they 
have infrequent need to take them. Further research should be done in order to assess the 
relationship between pill-taking status and sociodemographic variables. Additionally, a more 
randomized sample of general Americans should be studied to further understand healthy 




With an increasing number of Americans taking prescription medications and over 55% 
taking them regularly, the act of “pill-taking” has become a stereotyped convention. This 
percentage has been increasing each year and has increased 10% in the last decade alone 
(Dennis, 2015). The research community has been particularly interested in the stigmas 
surrounding the frequent use of prescription medications. A person is given the “pill-taker” 
identity when they are comfortable taking over-the-counter or prescription drugs in their daily 
life. The pill-taker identity has several negative connotations in the view of the general public, 
including that pill-takers are over-treating their disease or are unwilling to make lifestyle changes 
such as modifying their diet or exercising (Polak, 2017). The pill-taker identity brings with it 
both public stigma and self-stigma, especially when patients appear to be dependent on 
medications (Kranke, Floersch, Townsend, & Munson, n.d.; Lien et al., 2017). Self-stigma 
results from the internalization of public stigma and has been shown to negatively affect 
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relationships, self-esteem, willingness to seek opportunities, and adherence to medical services 
(Kranke et al., n.d.).  
People may avoid taking medications for several reasons that are associated with stigmas. 
First, people may feel negatively towards “over-medicating” since the over-medicalization of 
health is a significant issue in the United States (U.S.), wherein medical practices with no clear 
benefits are promoted (Parens, 2013; Polak, 2017). Second, some people would rather make 
lifestyle or behavioral changes to improve their health, rather than be reliant on medication. 
These issues further perpetuate a tension for pill-takers between embracing medical 
advancements and maintaining a “natural” lifestyle by resisting medicalization. Both public and 
self-stigma associated with having a pill-taker identity may prevent people from seeking or 
adhering to effective treatment options (Kranke, Floersch, Kranke, & Munson, 2011; Kranke et 
al., n.d.). 
The identity of the pill-taker is related to Phase I clinical trial participants, who are 
typically considered “healthy” individuals and do not suffer from any serious or life-threatening 
conditions. Phase I clinical trials are conducted to learn if a drug or treatment is safe and what 
type of side effects result (The American Cancer Society, 2017). The main concern of Phase I 
trials is to understand the extent to which the treatment affects the body and how the body reacts 
to the treatment (The American Cancer Society, 2017). Phase I trial participants serve as a 
relevant population with whom to study the stigmas surrounding pill-takers because they are 
healthy participants who have little need to take prescription medications. Additionally, Phase I 
participants are paid to test new pharmaceuticals and could have more nuanced views of the risks 
of taking pharmaceuticals when compared to the general population (Fisher, 2015). Lastly, these 
individuals are required to meet certain health standards in order to qualify for clinical trials, 
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such as a BMI range or a blood cell count (“Clinical Trials and Screening: What You Need to 
Know,” 2015). As a result, they often place a large value on and have more knowledge about 
their own health when compared to others (Monahan & Fisher, 2015).  
Medications play an essential role in the lives of both sick and well people, but studies 
surrounding the healthier subset of the population are lacking. Currently, much of the scholarly 
literature focuses on stigmas for specific classes of medications or treatments. A gap in the 
literature exists for how generally healthy individuals perceive pharmaceuticals and the pill-taker 
identity. This study will explore how Phase I trial participants’ perceptions of medications differ 
across several sociodemographic factors and how the role of a Phase I clinical trial participant 
interacts with the pill-taker identity. Thus, the proposed research project will aim to investigate 
the following questions:  
• What can we learn about the identity of being a pill-taker from healthy Phase I trial 
participants who are paid to take pharmaceuticals? 
o How does the identity of being a pill-taker differ across gender, race, age, and 
socioeconomic status?  
• How does the Phase I trial participant’s overall concern for their health correlate with 




Dennis (2015) found that the prevalence of prescription drug usage for American adults 
rose from 51% to 59% between 2000 and 2012. This expansion of medication usage has been the 
result of a complex interaction of factors: aggressive drug promotion by the pharmaceutical 
industry, consumer preferences for drugs, improved medical technology, and increased coverage 
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by insurance companies and the government (Busfield, 2010). The pharmaceutical industry has 
been a large driver of prescription drug usage; promoting pill-taking has been seen as a way to 
solve medical problems “as if by magic” (Busfield, 2006, p.310). Perceptions of medications 
across demographic groups are important to consider in the growing landscape of 
pharmaceuticals in the U.S., a multibillion-dollar industry making up over 10% of U.S. 
healthcare spending (CMS.gov, 2015). 
The act of pill-taking has become common in modern culture; however, many patients 
choose to reject the pill-taker identity. One study found that patients regularly taking statins, 
drugs that reduce levels of fats, tend to reject  from the pill-taker identity (Polak, 2017). The 
Drugs and Therapeutics Bulletin also uses this language with negative connotations to describe 
how the United Kingdom has become a nation of pill-takers after 50% of women and 43% of 
men reported taking at least one prescribed medication in the past week (“The UK: a nation of 
pill takers?,” 2015). While the explicit “pill-taker identity” has been relatively unexplored in 
literature, concepts related to the stigmas of pill-taking are commonly discussed. 
Literature describes two forms of stigma surrounding taking medication that can 
influence patient behavior, public stigma, and self-stigma. Public stigma refers to discrimination 
by others, whereas self-stigma refers to internalization of these negative stereotypes (Pattyn, 
Verhaeghe, Sercu, & Bracke, 2014). Stigmas surrounding medications and their overall health 
implications are barriers for pill-takers to treatment or recovery. Public and self-stigmas present a 
barrier to recovery and provide reasons for noncompliance with medication treatments. For 
example, medication adherence for antidepressants and the process of seeking treatment from 
health professionals have been associated with lower perceived stigma and higher self-described 
severity of illness (Martinez, Xu, & Hebl, 2017; Sirey et al., 2001). Additionally, an 
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asthma/allergy drug compliance study found that stigma associated with medication usage 
involved the idea that medicine “damages your body and your identity” without curing the illness 
(Hansson Scherman & Löwhagen, 2004).  
First, both public and self-stigmas are further perpetuated when individuals are hesitant to 
contribute to the over-medicalization of health. As described by the previously mentioned study 
regarding statins, pill-takers are often balancing conflicting moral dilemmas: deferring to 
medical expertise, but not being overly deferential, as well as being concerned with one’s health, 
but not too concerned (Polak, 2017). Polak describes this phenomenon as “reflecting a broader 
tension between rival tropes: embracing medical progress and resisting medicalization” (Polak, 
2017, p.608)  
Second, both public and self-stigmas can depict the notion that lifestyle changes are 
valued over medication treatments. This type of conflict is presented in literature comparing 
pharmacotherapies and behavioral interventions for specific diseases. For example, in the 
treatment of adolescents with opioid use disorder, many patients and families believe that 
medications should be used as a last resort following other forms of treatment (Bagley, Hadland, 
Carney, & Saitz, 2017). On the other hand, the American Academic of Pediatrics believes that 
adolescent opioid use disorder should primarily be treated with pharmacotherapies. These 
reasons why pill-taker labels are avoided exemplify how forms of stigma can alter perceptions of 
medications.   
 Past and current research has focused on pill-taking and medication usage for individuals 
with specific conditions and not on the majority healthy population. Very limited literature exists 
on Phase I trial participants, or other healthy individuals, and their perceptions of medications. 
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This study will aim to further understand stigmas and the healthy individual’s experience with 
medication in the context of the culture of medication usage.   
 
Methods 
Data Source  
This qualitative study was conducted in order to investigate healthy Phase I trial 
participants’ perceptions of over-the-counter or prescription medications and the pill-taker 
identity. The data utilized in this study is from the larger five-year project beginning in 2013, 
Healthy Voices On their Involvement and Clinical Experiences in Studies, also known as 
“HealthyVOICES,” that aims to understand experiences of healthy volunteers in Phase I clinical 
trials (Edelblute & Fisher, 2015).  Participants were recruited from seven Phase I clinics across 
the Eastern, Midwestern, and Western regions of the U.S., with 180 participants enrolling in the 
study (Cottingham & Fisher, 2016; Edelblute & Fisher, 2015). Equal numbers of participants 
were recruited from each of these regions in the U.S. Each participant needed to have completed 
or screened for at least one Phase I clinical trial prior in order to qualify for the HealthyVOICES 
study.  
Participants consented to five semi-structured interviews over the course of three years 
(baseline, 6-month, 1-year, 2-year, and 3-year) about their experiences as healthy study 
participants. Semi-structured interviews were completed using an interview guide, but this 
method also utilized probing questions to explore unprompted themes that are important to study 
participants (Robert Wood Johnson Foundation, n.d.). All participants were compensated with 
the respective values for each of the five interviews completed: $20, $50, $100, $100, and $200. 
HealthyVOICES was funded by a grant from the National Institute of General Medical Sciences 
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of the National Institutes of Health (NIH) and underwent an ethics review by the University of 
North Carolina at Chapel Hill Biomedical Institutional Review Board.  
An in-person “baseline” interview was conducted after initial enrollment of participants. 
The remaining four waves of interviews were conducted via telephone. Following the baseline 
interview, the participant group was randomly split into a 20% “control arm” and an 80% “full-
participation arm.” The control participants completed only baseline and 3-year interviews while 
having only limited contact with the study team throughout the study duration. The control arm 
allowed us to measure unintended intervention effects on the clinical trial participants. Data 
collection for the HealthyVOICES project has been completed, and preliminary findings have 
been published (Edelblute & Fisher, 2015). Out of the original 180 participants, 34 were 
randomized to the control arm. We retained 91.1% of the participants. Of those not completing 
the study, 3 self-withdrew, 2 were withdrawn by the study team, and 11 were lost in follow-up.  
 
Sample 
 This study utilizes data collected surrounding medication usage that was collected from 
the 1-year and 2-year interviews of the full-participation arm and includes interviews from 131 
participants (there were 261 interviews total1). Our sample reflects the typical age, race, and 
socioeconomic status of Phase I clinical trial participants that are found in similar studies (Fisher 
& Kalbaugh, 2011) [Table 2]. Further demographic information was collected, including 
education, employment status, and household income. The sample was not randomly generated 
but sought a diverse group of healthy volunteers across geographic regions and clinic types 
(academic, pharmaceutical-owned, privately owned, and contract research organizations).  
                                                      
1 One participant did not complete his 2-year interview. 
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 Although several demographic factors, such as household income or employment status, 
may have changed modestly between the 1-year and 2-year interviews, the initial 1-year 
demographic data was used in the analysis for this study. The racial/ethnic breakdown of the 
study population is as follows: 39% Black or African-American, 27% Non-Hispanic White, 22% 
Hispanic, and 10% More than one race. The majority of the study population falls between the 
ages of 30-49, but all participants ranged from ages 18-64. The breakdown of the participants’ 
highest attained educational level is as follows: 22% Bachelor’s degree or higher, 29% Some 
college, 12% Trade/technical/vocational training, and 20% High school or GED. The majority of 
the sample had a household income of $25,000 or higher (60%). In terms of employment status, 
participants were employed full-time (36%), self-employed (25%), or not employed (21%). The 
number of clinical trials that study participants had enrolled in is noted under the category of 
“Clinical Trial Experience.” The majority of study participants (65%) had completed at least 5 
studies at the 1-year interview mark.  
 
Table 2. Demographic Breakdown of Study Participants (N = 131) 
 
n  % 
Clinical Trial Experience 
  
1 study 20 15.3% 
2-4 studies 26 19.8% 
5-10 studies 36 27.5% 
11-45 studies 49 37.4%    
Race/Ethnicity 
  
Non-Hispanic white 45 34.3% 
Black 51 38.9% 
American Indian 1 0.76% 
Asian 1 0.76% 
More than one race 5 3.82% 
Hispanic1 29 22.1% 
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Age 
  
18-21 3 2.3% 
22-29 22 16.8% 
30-39 47 38.9% 
40-49 39 29.8% 




Less than high school 9 6.87% 
High school or GED 26 19.8% 
Some college 38 29.0% 
Trade/Technical/Vocational training 17 12.9% 
Associates degree 11 8.39% 
Bachelor degree 27 20.6% 




Employed full-time 47 35.9% 
Employed part-time 22 16.8% 
Not employed 28 21.3% 
Retired 1 0.76% 
Self-employed 33 25.2% 
   
Household Income 
  
Less than $10,000 15 11.5% 
$10,000 to $24,999 37 28.2% 
$25,000 to $49,999 57 43.5% 
$50,000 to $74,999 11 8.39% 
$75,000 to $99,999 4 3.05% 
$100,000 or more 6 4.58% 
1The category Hispanic includes all racial groups, of which we have those that identify as white, more 
than one race, and American Indian in our sample. 
2These data are based on consolidated definitions of each employment category that we used to 
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Measures  
Qualitative data analyzed for this study was prompted by questions from the interview 
guide [Table 1] related to pill-taking and medication usage that were asked to participants during 
their 1-year and 2-year semi-structured interviews. I categorized participants as: pill-takers, not 
pill-takers, or ambivalent, based on their self-identification and responses to interview questions 
[Table 1]. For example, participants who were categorized as not pill-takers claimed that they 
rarely, if ever, took medications, even when unwell. Those categorized as pill-takers described 
taking medications regularly or feeling comfortable taking pills when unwell. Themes 
surrounding medication usage were found based on categories of gender, race, age, 
socioeconomic status, and overall health investment. The measure of overall health investment is 
derived from qualitative data but is used to categorize the level of involvement that participants 
describe regarding their health2. Participant sociodemographic data from the 1-year interviews 
were used to conduct significance testing between the pill-taker identity and demographic 
variables. However, no statistically significant relationships were identified through this analysis. 
This could be due to small sample size, or due to the lack of true differences. Therefore, this 
paper primarily explores the qualitative data.  
 
Table 1. Interview Guide Questions pertaining to Pill-Taking 
 
One-Year Interview 
• How often do you take prescription medications? 
• How appropriate do you think these medications are for treating minor problems, like 
headaches, indigestion, gas, etc.? 
o  [For participants who claim never to use these products] How long have 
you avoided using them? Why do you avoid these products? 
Two-Year Interview 
• What do you typically do when you get sick? 
                                                      
2 Overall health investment categories: healthy plus, healthy, wannabe healthy, non-health 
conscious, and unsure.  
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• When you were growing up, what was your family’s typical response when you or 
someone else was sick? 
• Now that you have participated in clinical trials, how does this shape your view 
of medications? [Safer? Riskier? How much research do you do?] 
 
Data Analysis  
  Qualitative data collected from all interviews was transcribed in full by an independent 
transcription company. Following transcription, a research team member verified the transcript 
to ensure that it sufficiently matched the original audio and made corrections as necessary. The 
transcripts were then preliminarily coded by at least two members of the research team according 
to a predetermined coding structure that was developed using clinical trial literature, research 
conducted on healthy volunteers, and the specific themes probed as part of the two interview 
guides. These coded excerpts became the raw data for the current study.  
To complete the first wave of analysis on this data, we identified participants’ responses 
to interview questions that pertained to pill-taking and medication usage [Table 2]. These 
responses had been given the parent code “Health/Mental Health” with the child code 
“Information/Orientation,” which has been defined by the research team as: health information or 
perceptions of pharmaceuticals, OTC medications, drug consumption, and attitudes/responses to 
sickness. In the second wave of analysis, I evaluated participants as pill-takers, not pill-takers, or 
ambivalent. The ambivalent category was created during the second-wave coding process 
because many participants simultaneously expressed elements of pill-takers and not pill-takers. 
Selected excerpts were also chosen for further analysis by secondary inductive coding to reveal 
themes across the sociodemographic variables described above. In my presentation of the 
findings, pseudonyms are used to protect the confidentiality of the participants. The race, age, 
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 Participating in Phase I clinical trials gave study participants unique perspectives on pill-
taking. Since these participants are healthy individuals, their perceptions of the pill-taker identity 
were likely to be less biased towards a particular drug or treatment and more representative of 
the general U.S. population. However, Phase I trial participants are more likely to be part of 
underrepresented minority groups, which poses another element to consider for this analysis. The 
quantitative data showed no significant relationships between pill-taker status and age, race, 
socioeconomic status, or gender. Nonetheless, qualitative data reflected broader themes for pill-
takers overall and their perceptions of medications. Narratives regarding pill-taking were 
reflective of national trends of medication usage seen in the literature, but further described the 
complexity of this issue.  
Given the sample of 131 participants, 41 (31%) were pill-takers, 54 (41%) were not pill-
takers, and 14 (11%) were ambivalent [Table 3]. Pill-takers were comfortable with the idea of 
taking pills regularly, such as for a headache or a fever. Not pill-takers were typically against 
taking medications overall and expressed negative feelings towards pills. Ambivalent participants 
often expressed views of pill-takers and not pill-takers simultaneously. Given the unprompted 
nature of participant responses, 22 participants (17%) could not be categorized as pill-taker, not 
pill-taker, or ambivalent due to lack of information. In this study, I focused on the responses of 
the not pill-takers and those who were ambivalent, as they presented unique perspectives as to 
what has been previously seen in the literature. For the purposes of preserving the identity of our 
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study participants, pseudonyms are used to describe the quotes below. I highlight here four 
critical themes about pill-taking that were particularly prevalent for these Phase I trial 
participants: (1) natural/herbal remedies are preferable alternatives to pill-taking; (2) pills are 
dangerous chemicals and harmful to the body; (3) healthy individuals can be ambivalent about 
medications; and (4) pill-taking is related to the flawed medication culture in the U.S.  
 
Table 3. Pill-taking status determined for study participants (n=131) 
Pill-taker Identity Number of participants (percent) 
Yes 41 (31%) 
No 54 (41%) 
Ambivalent 14 (11%) 
Missing data 22 (17%) 
 
Natural/herbal remedies are preferable to pill-taking 
Out of the 54 study participants that were considered not pill-takers, 33 (61%) discussed 
preferring natural or herbal alternatives to taking medications. This narrative was prevalent for 
participants across all demographic factors. For example, Tracy, an African-American woman in 
her 20s, felt that medications are not effective in curing diseases, but rather in treating related 
symptoms. In her opinion, a more natural method of healing would actually treat the root cause 
of the illness: 
At the same time, I’m a firm believer in more natural ways of healing. I think 
chiropractor, accu- acupuncture, like I would rather do that than take a pill because I 
know that pills don’t cure any illness. What they do is, all they do is mute symptoms. So 
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you’re taking these pills, you mute your system or your symptoms. “Congratulations. 
They’re not making you any better.” (Two-year) 
This idea – that holistic or natural treatments are superior to all other pill-taking remedies – was 
consistent throughout many narratives. While many people cited natural methods as being safer, 
healthier, and more effective, other participants preferred these methods because they were 
accustomed to them through their upbringings or cultural backgrounds. Gilbert, a white Hispanic 
participant in his 40s, talked about how he has never really used medications much, but he puts 
more stock in the efficacy of home remedies:  
I don’t take any for even like a headache, not even Tylenol for my head, not even for that 
because I don’t like to (laughs). I don’t like them. I thought about it and I have never used 
medications much. Here is something extra that I recommend to you: For example, 
yesterday I was really tired and my head hurt, and what I did was smell a lemon, and if 
you do that, your headache quickly goes away. It is much more effective than a pill. 
(One-year) 
Among participants, similar home remedies were very commonly discussed, such as using 
lemons, potatoes, peppers, and sodas to get rid of headaches or fevers. Andy, a white man in his 
40s who grew up in Romania, discussed the natural tricks his mother used for getting rid of 
illnesses when he was growing up:  
Oh, we had all kinds of like home remedies. If you had a bad cough, my mom would 
wrap slices of potatoes on your neck, and then she would also use cornmeal around your 
neck and stuff and that usually took care of it…Let’s say you had a bad cold, she’d have 
some, some plum brandy, which is like really, you know-. I don’t like to drink, but it’s a 
heavier brandy, like a very strong brandy. Mix it up with a bunch of peppers, and you’ll 
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be fine and usually it works. Because there was so much belief in it, it usually just 
worked. So there were a lot of home remedies available. (Two-year) 
Andy stated that “there was so much belief in it, it usually just worked,” indicating that these 
forms of healing were widely known and accepted by his family. He seems to acknowledge some 
elements of the placebo effect when discussing these remedies as well. In particular, similar 
types of home remedies were often discussed among Spanish-speaking participants. Overall, the 
most common reason for participants choosing to not take pills was because they preferred to 
take natural/herbal remedies. 
 
Pills are dangerous chemicals and harmful to the body 
Many participants discussed how they did not take pills because they did not want to 
contaminate their bodies with unnatural substances. This notion that pills and medications are 
foreign and dangerous for the body is an idea that is closely tied to the previously discussed 
theme of natural and herbal remedies. However, these quotes exemplify one of the many 
negative connotations of being a pill-taker. For example, Harry, a multiracial man in his 20s, 
discussed how he prefers methods that do not involve chemicals: 
I just, I don’t know. I like natural remedies better. I just think the human body can really 
overcome most things without resorting to drugs. Those are just bad (laughs) for you, you 
know. You’re just messing with the chemicals. (One-year) 
Harry also touched on the idea that medications are not good for your body, and that natural  
alternatives will not damage the body in the ways that pharmaceutical drugs can. Many 
participants expressed further elements of distrust in the pharmaceutical industry and in the 
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effectiveness of medications. Jesse, a white Hispanic man in his 30s, neither trusts prescription 
drugs nor the way they are regulated overall:  
Like I’m not really for medication, like the FDA or shit like that. I know medication 
doesn’t help people, especially like prescription medication. They do a lot more harm 
than good. So, I mean, I’m pretty sure you know about like prescription overdoses and 
stuff like that, how there’s more, more prescription overdose deaths than there are, you 
know, say other things going on. So like I don’t really think medication helps people… If 
I had a choice to like help people and heal people, I would rather do it naturally and 
holistically rather than them take medication. (Two-year) 
Omar, a multiracial Hispanic man in his 30s, added a different perspective on this narrative. He 
discussed how drugs can lose their efficacy if taken too often: 
I generally don’t like chemicals. (laughs) That’s really what it boils down to... Usually, 
when people offer me Ibuprofen, it’s minor discomfort, you know. I feel like I’d rather 
just tough it out than do that. One day, I might be really in some pain and I want that 
Ibuprofen to work like gangbusters. You know what I’m saying? Or that Tylenol or that 
Nyquil, I want it to work like really well, so I don’t want to build any kind of tolerance to 
it. (One-year) 
Omar claimed that he typically does not like adding chemicals to his body, but he acknowledged 
their strength and usefulness. He would take a pill if necessary but would reject the pill-taker 
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Healthy individuals can be ambivalent about medications 
In the initial analysis, participants were considered to be pill-takers or not pill-takers. 
However, further data analysis revealed that healthy participants were more complex than this. 
Because these participants are considered healthy, several patients did not have strong opinions 
on pill-taking since they have no need to take medication in their everyday lives. These opinions 
about taking medications were considered ambivalent, or in two minds about medications; they 
would take pills if necessary but would not do so generally. Out of all participants, 14 (11%) of 
the sample were considered ambivalent about pill-taking. For example, Zach, a white man in his 
30s, was critical yet understanding of people taking medications: 
I’m cynical of it because, partially because I’m-I’m a healthy person. I don’t have any 
crazy diseases or conditions. I stay in shape. I try to eat well. I’ve always tried to be, you 
know, I’m gonna try to not get sick or get that condition in the first place by living a 
healthy life. Now I realize there are plenty of people that no matter how healthy they are, 
they’re still gonna have a disease or get some condition and they can’t help it. And so I 
understand. I mean, I’m not totally condemning modern medicine—you know what I 
mean?—of being some shady enterprise. But I think that I’m a, I’m a big believer in not 
going straight to the pharmaceutical drug when you have an issue. (Two-year) 
Similarly to Zach, Michael, an African-American man in his 30s, expressed both elements of a 
pill-taker and not a pill-taker in his responses. In particular, Michael seemed averse to being 
labeled as a pill-taker:  
It really has to be bad for me, like it really has to be bad for me to really like feel like I 
can do that. If I feel like I can tough it out and not do that, then, you know, I’ll do that... 
But don’t get me wrong, I will take an aspirin if I feel like I need to take one. I’m not 
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gonna just sit there and make myself suffer…if I really feel like I really need to take 
something for like my allergies, if I happen to have some allergy, I may take something 
then. (One-year) 
Michael wanted to ensure that we know that taking pills is not his first line of defense when 
feeling unwell, but he will if necessary.  
 
Pill-taking is related to a flawed medication culture 
One reason many people avoid the pill-taker label is because of the medicalization of 
health that is seen in the U.S. Even as Phase I trial study participants who earn income by taking 
medications, they are often critical of medication culture for many reasons. According to Roscoe, 
an African-American man in his 40s, dependence on medication is common and that is one 
reason why he identified as not a pill-taker:  
I just know there’s a lot of people that I know that become dependent on, on medication, 
and I’d say a majority of the world pretty much that, you know, there’s doctors, doctors 
prescribe something every time and the people just live on that and I don’t, I don’t like 
that. (One-year) 
Overprescribing habits were commonly cited as reasons for flawed medication culture. Chad, a 
white man in his 50s, described how surprised he was that his brother was taking so many 
medications and was still able to function normally. Similar to Roscoe, he discussed the issues of 
over-prescription:  
I think doctors overprescribe medicines. But I’ve got a brother who takes like forty or 
fifty medications at one time. We’re amazed that he can, he can take all of those and still 
function and not have too bad of side effects. (Two-year) 
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Participants knew people who are addicted to medications, and they attributed this to the “pill-
popping” culture, where pharmaceutical drugs are always the first line of defense. Theresa, an 
African-American woman in her 50s, had similar opinions but described a personal example of 
why she chose to not take pills:  
Well, I mean, I would, I’ve seen, just looking at people, and how they become so 
dependent on a pill for this, a pill for that, and what made me just start looking for more 
being more healthy was because of my mother passing at such a young age. So I wanted 
to make sure that I took care, you know, really good care of myself. But at the same time, 
I would see people where they were just so dependent on pills and knowing that it was 
just a bandage instead of getting to the whatever the actual problem was. So that’s what 
was just always been a turnoff for me. (One-year) 
Theresa also talks about how being dependent on pills is “just a bandage” on the problem, and 
about how it is not truly solving anything. This is a common theme that people who preferred 
natural methods over medications also discussed, but Theresa goes a step further by criticizing 
the medical system for the way it treats diseases or illnesses. Many participant responses claimed 
that natural methods are more comprehensive and superior to medications, but they do not give 
evidence or reasoning to support these ideas. Beyond a dependence on medications, Zoe, a white 
woman in her 30s, brought up the environmental issues that follow the pharmaceutical industry’s 
actions: 
But when I think of drugs overall, it’s still feels like there’s a lot of them, and a lot of 
them that are, you know, affecting people and just the world and environment in ways 
that we’re not gonna acknowledge or realize for a long time…We, you know, don’t deal 
with things and take medicine instead of trying to figure out what the cause is, other than 
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just pain or whatever. And also in terms of just the amount of contamination and just 
disposing of drugs that’s affecting water and soil and stuff for people. (Two-year) 
Zoe expressed how pill-taking can result in even more negative consequences for the world 
around us. This narrative is indicative of the fact that participants recognized that the pill-taking 
culture has much larger societal effects beyond individual health.  
 
Discussion  
Prescription and over-the-counter drug usage in the U.S. continues to increase, and 
healthy participants’ opinions reflected this dynamic climate. The original intent of this study 
was to understand how medication usage differs across several sociodemographic factors for 
healthy people: age, race, socioeconomic status, and gender. However, through this study, 
broader trends in medication usage for healthy Phase I trial participants were found, which will 
contribute to the currently limited literature on pill-taking. While no statistically significant 
differences were found within this sample of participants between pill-taking status and 
sociodemographic factors, it is likely that when looking at the larger U.S. population, these 
trends in pill-taking may be more evident. For example, the national opioid epidemic 
disproportionately affects white, poor, and rural populations, and black patients are half as likely 
to be prescribed medications when compared to white patients (Clarke, Skoufalos, & Scranton, 
2016), (Holpuch, 2016). It may also be possible that there are no true differences across 
sociodemographic factors and pill-taking status. The U.S. as a whole is experiencing a cultural 
phenomenon with regards to increased medication usage, and it is likely that different 
demographic groups are equally affected.  
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I identified major themes related to stigmas surrounding medication usage that 
contributed to existing literature. The first three themes discussed were previously unexplored 
ideas in pill-taking literature: (1) natural/herbal remedies are preferable alternatives to pill-
taking; (2) pills are dangerous chemicals and harmful to the body; and (3) healthy individuals 
can be ambivalent about medications. The final theme discussed, (4) pill-taking is related to a 
flawed medication culture, built upon previous literature about medication culture and the over-
medicalization of health. 
Overall, participants largely felt that natural or herbal remedies were more effective 
alternatives to taking medications, and many thought that by taking pills, they were 
contaminating their bodies. Reasons that are indicative of why people may choose to avoid the 
pill-taker identity were largely based in both public stigma and self-stigma. Particularly relating 
to self-stigma, many of the participants implied that taking pills would affect their self-image or 
self-worth (Kranke et al., 2011). Issues relating to public stigma are prevalent when looking at 
the fourth theme of the flawed medication culture, as participants often blamed addiction and 
physicians’ overprescribing habits for contributing to the negative “pill-popping” culture that 
exists in current society.  
The idea that everyone is taking pills and that they are not truly getting at the root cause 
of medical issues was a common attitude that contributed to public stigma surrounding those 
who are pill-takers as well. This theme is also related to the previously discussed over-
medicalization of health, which describes the phenomenon of every little health issue being dealt 
with as a medical issue, in this case by pills or medications (Parens, 2013). However, some 
participants even discussed the importance of refraining from taking medications in order to 
preserve their efficacy. They believed that taking too many medications would cause their body 
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to build up a tolerance to the medication. This shows that the over-medicalization of health idea 
supports not pill-takers’ narratives in different ways. They are supported by those who think 
medications are ineffective, as well as by those who think they are effective but can lose efficacy 
through overconsumption.  
This study found that it is difficult to categorize individuals as pill-takers or not pill-
takers. That participants are healthy makes the process of categorizing them even more difficult, 
because at times it was difficult to know what they would do if they became ill. Moreover, study 
participants had varying opinions on medications, and because they were typically healthier, they 
oftentimes had not formed strong opinions on medications. While completing the secondary 
analysis, a third category of “ambivalence” was created, which made up a significant percentage 
of the sample. The creation of the ambivalent category contributes to the pill-taking literature 
because it demonstrates the complexity of this issue is in the U.S. Many factors contribute to 
whether a person chooses to take pills or not, and these factors can change over time or by 
circumstance.  
The majority of the results presented in this study were from participants who were 
categorized as either ambivalent or not a pill-taker. One area in the pill-taker literature that could 
be worth exploring is the idea of the placebo effect, which is when an individual’s expectations 
of the pill can cause their own body’s chemistry to display effects similar to what the medication 
would have done (“The Placebo Effect: What Is It?,” 2018). Because the most commonly cited 
reason for not taking pills was due to preferring natural or herbal remedies, it is worth noting that 
the placebo effect could be occurring for many of these participants. The idea that the placebo 
effect could occur so commonly and contribute to why people choose not to take pills is a 
cultural phenomenon to consider.  
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As Phase I trial participants who are being paid to take pharmaceuticals, the plurality of 
the sample was categorized as not pill-takers. Many participants reflected mistrust in the 
pharmaceutical industry and separated the pill-taking they do in trials from pill-taking for 
personal reasons. Some even noted that pill-taking could potentially diminish their chances for 
qualifying for Phase I trials, so they choose to refrain from consuming all unnecessary pills. 
While being not a pill-taker may seem contradictory to their role as healthy volunteers, it makes 
sense as to why they may be cautious about the long-lasting effects of pills. This presents an 
interesting paradox for healthy volunteers as they often alter their perceptions of pill-taking for 
the purpose of their roles in Phase I studies.  
 
Limitations 
  The primary limitation of this study is that the data is self-reported from unprompted 
responses. This means that our characterization of the participant as a pill-taker, not a pill-taker, 
or ambivalent may not have been fully reflective of the participants’ true behaviors or opinions 
on medications. This data was collected as part of a secondary analysis of the HealthyVOICES 
project, which did not have the original intent of investigating the research questions that I 
posed. There were approximately 22 (17%) participants that did not have sufficient qualifying 
data in their responses to categorize their pill-taker identity. This even further limited the data 
that the study utilized in order to draw associations between demographic factors and pill-taking 
status.  
Recruited participants for this study were healthy volunteers who participate in Phase I 
clinical trials. While clinical trial participants are typically healthy individuals, the results found 
for this specific population may not be generalizable to the larger healthy population in the U.S. 
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Clinical trial participants are a unique and small population of individuals that might be 
unusually focused on their health or reflective about what it means to take pills. A more 
representative group would include a random sample of healthy adults in the U.S. 
 
Conclusion 
This project creates implications for further research studies associated with demographic 
trends and increased drug usage in the U.S. It is possible that pill-taking culture affects 
demographic groups equally, and that there truly is no significant relationship between 
sociodemographic characteristics and pill-taking status. Similar studies could also strongly 
inform literature on medication adherence to help providers understand factors relating to why 
patients may or may not adhere to certain medication regimens. In addition, these studies should 
take into consideration the unique and nuanced role of healthy individuals in the healthcare 
system. Understanding these cultural trends is essential for providers, patients, and healthcare 
organizations alike when considering treatment options and how to make sense of society’s 
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